PROTECTIVE PROPERTIES OF SYNOGENEOUS AUTOVACCINE SAMPLES
DOI:
https://doi.org/10.11603/1681-2727.2023.1.13923Keywords:
Pseudomonas aeruginosa infection, autovaccine, photodynamic inactivation of the pathogen, protectiveness of the vaccineAbstract
SUMMARY. The purpose of the work is to increase the protective properties of the blue pyogenes autovaccine obtained by the photodynamic method using improved technology.
Materials and methods. For the experiments, 170 purebred white mice weighing 18–20 g were used. The effectiveness of vaccination was evaluated by the LD50 indicators determined for the experimental (vaccinated) and control (non-vaccinated) groups of animals, with the calculation of the efficiency index (IE): the ratio of the experimental LD50 to the control LD50.
Research results. It was established that the autovaccine is non-toxic and non-allergenic. When studying the protective activity of the received vaccine samples, one week after vaccination, mice were infected intraperitoneally with a homologous strain of P. aeruginosa at a dose of 5×109 microbial cells, which corresponded to 5LD50.
The same dose of culture was administered to non-immunized mice – the control group. In this group, about 60 % of the animals died within the first five days, and during the entire observation period (15 days), this indicator increased to 80 %.
Immunization of mice with the developed autovaccine made it possible to reliably reduce lethality (χ2<0.05), which did not exceed 20 %. In groups of experimental animals, even when they died, it was possible to extend their lives up to 10–15 days.
The results of a comparative study of 3 series of autovaccines showed that all of them had a significantly positive effect compared to the control group of mice (χ2>0.05, p<0.01).
Conclusion. The obtained research results indicate the effectiveness of the application of the developed technology for obtaining anthrax vaccines and their protective activity. This indicates the prospect of introducing autovaccinotherapy into health care practice, which is especially important during martial law.
References
Peng, Y., Bi, J., Shi, J., Li, Y., Ye, X., Chen, X., & Yao, Z. (2014). Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care–associated infection control in the hospitals of Southern China: A case-control surveillance study. American Journal of Infection Control, 42 (12), 1308–1311. DOI: https://doi.org/10.1016/j.ajic.2014.08.006
Fan, N., Hu, Y., Shen, H., Liu, S. (2020). Profiling of patogens Compositional and drag-resistance profiling of patogensin patients with severe acute pancreatitis: a retrospective study. BMC Gastroenterol., 1, 20 (1), 405. DOI: https://doi.org/10.1186/s12876-020-01563-x
Nerobeev, V. D., Nerobeev, D. V. (1988). Vaccination: effectiveness and safety, problems and prospects. Novosti meditsiny i farmatsii – News of Medicine and Pharmacy., 10, 34–36 [in Russian].
Giedrys-Kalemba, S., Czernomysy-Furowicz, D., Fijałkowski, K., & Jursa-Kulesza, J. (2018). Autovaccines in individual therapy of staphylococcal infections. In Pet-To-Man Travelling Staphylococci (pp. 253-264). Academic Press.
Volosach, O. S., Kuzmych, I. A., Zayats, Y. K. (2017). Microbiological efficacy of autovaccination therapy in Pseudomonas infection. elib.grsmu.by. Retrieved from http://elib.grsmu.by/bitstream/handle/files/5197/13-16.pdfz.pdf?sequence=1 [in Russian].
Method of preparation of autovaccine (2001). Pat. 39700 Ukraine. No. 2000127520; appl. 26.12.2000; publ. 15.06.2001, 5 [in Ukrainian].
Galapero, J., Fernández, S., Pérez, C. J., Calle-Alonso, F., Rey, J., & Gómez, L. (2019). Exploring the importance of mixed autogenous vaccines as a potential determinant of lung consolidation in lambs using Bayesian networks. Preventive Veterinary Medicine, 169, 104693. DOI: https://doi.org/10.1016/j.prevetmed.2019.104693
Daniel, G. V., Laura, S. V., Jose, B. P., Enrique, C. A., Enrique, C. G., Juan, G. G., & Mateo, P. M. (2014). Autovaccines for chronic urinary tract infections; ten years follow-up experience. American Journal of Life Sciences, 2(6-3), 13–17.
Priebe, G. P., & Goldberg, J. B. (2014). Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert review of vaccines, 13 (4), 507–519. DOI: https://doi.org/10.1586/14760584.2014.890053
Vincent, J. L. (2014). Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future microbiology, 9 (4), 457–463. DOI: https://doi.org/10.2217/fmb.14.10
Volosach, O. S. (2011). Clinical example of successful treatment of autovaccinal mixed infection complicating the course of chronic furunculosis. Journal of GrSMU. 1 (33), 12–14 [in Russian].
Tarasko, A. D., Chelysheva, H. M., Kovalchuk, E. S., Khabibullin, A. M. (2007). Use of autovaccine in the treatment of recurrent and protracted purulent-inflammatory processes in the clinic. Stationary replacement technologies: Ambulatory surgery, 4, 221-222 [in Russian].
Volosach, O. S. (2017). Immunomodulating role of fungal-bacterial autovaccines, indicators of humoral immunity in patients with chronic inflammatory diseases complicated by candidiasis. Successes of medical mycology, 17(17), 227-233 [in Russian].
Giedrys-Kalemba, S., Czernomysy-Furowicz, D., Fijałkowski, K., & Jursa-Kulesza, J. (2018). Autovaccines in individual therapy of staphylococcal infections. In Pet-To-Man Travelling Staphylococci (pp. 253-264). Academic Press. DOI: https://doi.org/10.1016/B978-0-12-813547-1.00019-4
Jones, A. M., Govan, J. R., Doherty, C. J., Dodd, M. E., Isalska, B. J., Stanbridge, T. N., & Webb, A. K. (2001). Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. The lancet, 358(9281), 557-558. DOI: https://doi.org/10.1016/S0140-6736(01)05714-2
Burova, L. M., Burova, E. D. (2016). Antibiotic sensitivity of clinical isolates of Pseudomonas aeruginosa. Infektsiyni khvoroby – Infectious diseases, 3(35), 74-77 [in Ukrainian].
Westritschnig, K., Hochreiter, R., Wallner, G., Firbas, C., Schwameis, M., & Jilma, B. (2014). A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Human vaccines & immunotherapeutics, 10(1), 170-183. DOI: https://doi.org/10.4161/hv.26565
Method for rapid in vitro synthesis of bioconjugate vaccines via recombinant production of n-glycosylated proteins in prokaryotic cell lysates (2018). Appl. 20180016612A1. US. IPC C12P21/005. № US201715650127, filed. 2017.07.14, publ.18.01. 2018 [in Ukrainian].
The method of obtaining a vaccine for the prevention and treatment of pseudomonosis (2020). Pat. 143248 Ukraine: IPC C12N1/04(2006.01). № u2012908730; appl. 19.07.2019; publ. 07.27.2020, Bul. 14, 5 [in Russian].
Gorodnitskaya, N. I., Gabysheva, L. N., Derkach, S. A., Martynov, A.V. (2018). Immunoprophylaxis оf Pseudomonosis: аchievements аnd perspectives. Annals оf Mechnikov’s Institute, 2, 5-15 [in Russian].
Derkach, S. A., Horodnytska, N. I., Kutsai, N. M., Gabysheva, L. S. (June 2-4, 2021). The method of production auttovaccines from P. aeruginosa strains. The world of science and innovation proceeding of international scientific and practical conferencence, 413-420 [in Ukrainian].
Akhmatova, N. K., Kalynychenko, E. O., Kurbatova, E. A., Mykhaylova, N. A. (2019). Immunogenicity and protective activity of a recombinant vaccine against Pseudomonas aeruginosa infections. Immunology, 40, 4, 23-28 [in Russian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 I. S. Kovbasyuk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
